9 nmol/L, and is highly potent against ALK bearing the gatekeeper mutation L1196 M with an IC_(50) of 1.56 nmol/L. In the clinic, alectinib is highly efficacious in treatment of ALK-positive non-small cell lung cancer(NSCLC), and retains potency to combat crizotinib-resistant ALK mutations L1196 M, F1174 L, R1275 Q and C1156 Y.
非小细胞肺癌是危害人类生命最常见的恶性肿瘤之一,棘皮动物微管蛋白样4-间变性淋巴瘤激酶(echinoderm ONX-0914化学结构 microtubule-associated protein like 4-anaplastic lymphoma kinase,EML4-ALK)融合基因是新发现的非小细胞肺癌驱动基因,是非小细胞肺癌治疗的新靶点。EML4-ALK融合基因在非小细胞肺癌患者中的发生率约为4%~5%,并且在不伴有表皮生长因子受体(epidermal 
growth factor receptor,EGFR)突变或KRas突变的腺癌患者中的表达率约为42.80%。目前临床上用于治疗ALK阳性肺癌的药物为克唑替尼,同其他酪胺酸激酶抑制剂(tyrosine
kinase inhibitors,TKIs)相似,使用一段时间后也出现耐药。本文旨在介绍EML4-ALK融合基因结构特点、检测方法、ALK靶向药物的耐药机制以及逆转耐药的策略。
近年来,肺癌研究进展很大。在中国,有关肺癌的研究论文发表数量逐年增加,已成为仅次于美国的第二大肺癌研究大国。与结直肠癌和乳腺癌等其他肿瘤相比,肺癌的精准医疗开展得相对较早,发展也最快。1肺癌筛查与精准医学目前已有共识,筛查对于”捕捉”肺癌早期患者有效。肺癌的
目的分析腹腔炎性肌纤维母细胞瘤(IMT)的临床病理特点、诊疗方法及预后。方法回顾性分析经手术治疗的13例腹腔炎性肌纤维母细胞瘤患者的临床病理资料。结果本组患者女8例、男5例,中位年龄24岁(15~57岁)。临床表现为腹部肿物、腹部不适隐痛、发热、体重减轻等非特异性症状,影像学检查无明显特异性。SMA、MSA、Vim免疫组织化学检查均为阳性。本组患者均接受手术治疗,术后随访31~76月(中位44月),1例术后13月复发,再次手术后无复发,其余12例无复发和转移。结论腹腔IMT缺乏典型临床及影像学表现,明确诊断依靠病理检查,SMA、MSA、Vim多为阳性,有助于IMT的诊断,手术切除是首选治疗方法,预后良好。
2014年7月,美国癌症基因研究组(The
SP600125分子重量 CancerGenome Atlas,TCGA)在《Nature》上发布了230例可切除肺腺癌的包含DNA、mRNA、micro RNA水平的综合基因谱分析结果。通过对mRNA和DNA高通量测序结果及序列比对分析,发现约4%(10/230)肺腺癌因MET基因DNA水平第14外显子剪接区域(splice-sites)的突变导致MET第14外显子在mRNA水平出
Objective: This study aims to establish a method for highly parallel multiplexed detection of genetic mutations in Chinese lung cancer samples through Agena i PLEX chemistry and matrix-assisted laser desorption ionization time-of-flight analysis on Mass ARRAY mass spectrometry platform.Methods: We reviewed the related literature and data on lung cancer
treatments. We also identified 99 mutation hot spots in 13 target genes closely related to the pathogenesis, drug resistance, and metastasis of lung cancer. A total of 297 primers, composed of99 paired forward and reverse amplification primers and 99 matched extension primers, were designed using Assay Design software. The detection method was established by analyzing eight cell lines and six lung INCB024360 cancer specimens. The proposed method was then validated through comparisons by using a Lung Carta~(TM) kit. The sensitivity and specificity of the proposed method were evaluated by directly sequencing EGFR and KRAS genes in 100 lung cancer cases.Results: The proposed method was able to detect multiplex genetic mutations in lung cancer cell lines. This finding was consistent with the observations on previously reported mutations. The proposed method can also detect such mutations in clinical lung cancer specimens. This result was consistent with the observations with Lung Carta~(TM) kit. However, an FGFR2 mutation was detected only through the proposed method. The measured sensitivity and specificity were 100% and 96.